Cancer Supportive Care Drugs Market Size - By Drug Class (G-CSFs, ESAs, Anti-emetics, Bisphosphonates, Opioids, NSAIDs), Cancer type (Breast, Lung, Prostate, Colorectal, Melanoma), Distribution Channel (Hospital, Drug Store), Global Forecast (2023 – 2032)

Cancer Supportive Care Drugs Market Size

Cancer Supportive Care Drugs Market size was estimated to be USD 14.4 billion in 2022 and is predicted to increase at a growth rate of 1.9% till 2032. Progress in cancer treatments like chemotherapy, radiation therapy, targeted therapy, and immunotherapy has elevated treatment effectiveness. Prioritizing the well-being of cancer patients has gained significant prominence in cancer care.
 

The rise in awareness and education, the aging demographic, the growing inclination towards personalized medicine, and the growing population of cancer survivors have collectively emphasized the management of long-term treatment-related effects.
 

Moreover, the increasing global incidence and prevalence of cancer contribute to a growing patient population that requires supportive care. According to American Cancer Society, Inc. over 1.9 million new cancer cases is expected to be diagnosed in the U.S. in 2023. As more individuals are diagnosed with cancer, the demand for effective supportive care drugs to manage treatment-related side effects also rises.
 

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on the healthcare industry, including the cancer supportive care drugs market. Throughout the pandemic, various healthcare systems faced challenges with cancer treatment due to financial reallocation, lockdowns, and concerns about virus transmission.
 

Furthermore, numerous clinical studies for cancer medications, including supportive care drugs, were halted or postponed during the pandemic to prioritize patient safety. This interruption had implications for the development and testing of new supportive care drugs.
 

Nonetheless, telemedicine and remote healthcare services gained prominence during the pandemic to ensure patient safety. While certain supportive care services could be delivered online, the absence of in-person care might have influenced the overall management of treatment-related symptoms.
 

Cancer Supportive Care Drugs Market Trends

Cancer CareA New Era of Personalized Support Things are changing in the world of cancer care. Here are some of the exciting trendsPersonalized medicineDoctors are tailoring treatments to each patient's unique needs, considering their genetic makeup and overall health. Targeted therapies New drugs are being developed to fight specific side effects of cancer treatments, making them more tolerable. Digital healthMobile apps and telemedicine platforms are helping patients manage their symptoms and stay connected with their doctors. Long-term care Doctors are paying more attention to the long-lasting effects of cancer treatment and how to help patients cope. Combination therapiesSupportive care drugs are being used alongside cancer treatments to improve overall outcomes. Biologic agents These new drugs target specific pathways involved in treatment-related symptoms, providing more effective relief. These advancements are all about improving the lives of cancer patients by reducing side effects and providing the best possible support.

Cancer Supportive Care Drugs Market Analysis

Cancer treatments can sometimes affect the production of certain blood cells, like the ones that fight infection. To prevent this, doctors use drugs called cancer supportive care drugs. These drugs come in different types, like anti-nausea meds, pain relievers, and drugs that help your body make more blood cells. One type of cancer supportive care drug is called G-CSF. It helps your body make more neutrophils, which are white blood cells that fight infection. When you're getting chemotherapy, it can sometimes kill off these neutrophils, putting you at risk of getting sick. G-CSF helps prevent this by keeping your neutrophil levels up. In 2022, G-CSFs were the most commonly used type of cancer supportive care drug. They accounted for about 23% of all sales. This is because they are very effective at preventing infections and allowing people to get their full course of chemotherapy without any interruptions.

Different types of cancer require specific treatments, which can lead to a range of side effects. For breast cancer, which affects many women, common treatments include surgery, radiation, chemo, and targeted therapies. These treatments can cause discomfort, fatigue, and emotional challenges. To help manage these symptoms, special drugs called cancer supportive care drugs are available. They aim to improve patients' well-being and quality of life. In the United States alone, a large number of women are diagnosed with breast cancer every year.

Based on distribution channel, the cancer supportive care drugs market is segmented as hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a dominant industry share of 58.9% in 2022 and is expected to grow at a CAGR of 2% by 2032. Hospital pharmacists have specialized knowledge in oncology and supportive care drugs. They collaborate with healthcare teams to ensure appropriate drug selection, dosing, and administration based on individual patient needs.
 

Asia Pacific cancer supportive care drugs market accounted for significant revenue in 2022 and is expected to reach USD 6.1 billion in 2032 with a CAGR of 2.3% from 2023-2032. The Asia Pacific region has witnessed a rising incidence of cancer, attributed to factors such as population growth, aging, changing lifestyles, and environmental factors. As cancer cases increase, so does the demand for supportive care drugs to manage treatment-related symptoms.
 

Moreover, many countries in the Asia Pacific are adopting Western-style cancer treatments, including chemotherapy and targeted therapies. These therapies often come with side effects that require effective supportive care interventions.
 

Cancer Supportive Care Drugs Market Share

Major industry players operating in the cancer supportive care drugs market include

• Amgen, Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Heron Therapeutics, Inc.
• Novartis AG
• GSK plc
• F. Hoffmann-La Roche Ltd.
• Helsinn Healthcare SA,
• Teva Pharmaceuticals Industries Ltd.,
• Fagron Group.
   

Cancer Supportive Care Drugs Market Industry News

• In June 2020, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved NYVEPRIA (pegfilgrastim-apgf), a biosimilar of Neulasta (pegfilgrastim). NYVEPRIA was developed to reduce the risk of infection, as shown by febrile neutropenia, in patients with non-myeloid malignancies taking myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
   

The cancer supportive care drugs market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By drug class

• G-CSFs (Granulocyte-colony Stimulating Factors)
• ESAs (Erythropoiesis Stimulating Agents)
• Anti-emetics
• Bisphosphonates
• Opioids
• NSAIDs
• Other drugs

By cancer type

• Breast cancer
• Lung cancer
• Melanoma
• Prostate cancer
• Colorectal cancer
• Liver cancer
• Stomach cancer
• Other cancer types

By distribution channel

• Hospital pharmacies
• Drug stores and retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa